Ahmedabad-based CDMO and private-label manufacturer of generic pharma formulations — tablets, capsules, oral liquids, powders and external preparations — sold domestically and exported to 30+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 8 | 11 | 11 |
| Reserves | 1 | 7 | 35 | 44 |
| Borrowings | 13 | 14 | 8 | 12 |
| Other Liabilities | 8 | 10 | 5 | 10 |
| Total Liabilities | 27 | 40 | 59 | 77 |
| AssetsFixed Assets | 5 | 6 | 9 | 13 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 22 | 34 | 50 | 63 |
| Total Assets | 27 | 40 | 59 | 77 |
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ActivitiesCash from Operating | -12 | 6 | -15 |
| Cash from Investing | -5 | -2 | -9 |
| Cash from Financing | 17 | -4 | 27 |
| SummaryCapital Expenditure | — | — | — |
| Free Cash Flow | -17 | 4 | -23 |
| FCF Margin | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (3.7×) and current (8.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 4× exit, ₹143 only delivers your return if you pay ₹47. The price is currently baking in 34% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 4×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 18.71 |
| FY28 | 10.0% | 20.58 |
| FY29 | 10.0% | 22.64 |
| FY30 | 10.0% | 24.90 |
| FY31 | 10.0% | 27.39 |
| FY32 | 8.0% ·fade | 29.59 |
| FY33 | 6.0% ·fade | 31.36 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.